SCHEMBL5016181

SCHEMBL5016181

CCCCCNc1cccc2c(S(=O)(=O)NCC(=O)O)cccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.54
MEN1 O00255 1/20 0.53
TP53 P04637 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
TSHR P16473 1/20 0.53
CYP2C19 P33261 1/20 0.53
KMT2A Q03164 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
CA12 O43570 2/20 0.49
CA9 Q16790 2/20 0.49
CNR1 P21554 1/20 0.47
CNR2 P34972 1/20 0.47
FABP4 P15090 4/20 0.43
ALPL P05186 1/20 0.43
POLB P06746 1/20 0.43
NSD2 O96028 1/20 0.43
BRD4 O60885 1/20 0.43
NPY5R Q15761 1/20 0.42
RECQL P46063 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5016478 0.82 CNR1 (0.52) L3MBTL1MEN1TP53CYP1A2CYP3A4
SCHEMBL5022978 0.79 CNR1 (0.49) L3MBTL1MEN1TP53CYP1A2CYP3A4
SCHEMBL5015678 0.78 TSHR (0.51) L3MBTL1MEN1TP53CYP1A2CYP3A4
SCHEMBL30069272 0.76 CNR1 (0.57) L3MBTL1MEN1CYP1A2CYP3A4TSHR
SCHEMBL5016183 0.75 HDAC4 (0.47) MEN1TP53CYP1A2CYP3A4TSHR
SCHEMBL10815702 0.74 CNR1 (0.55) L3MBTL1MEN1TP53CYP1A2CYP3A4
SCHEMBL23346286 0.74 CNR1 (0.56) L3MBTL1MEN1CYP1A2CYP3A4TSHR
SCHEMBL30069294 0.74 CNR1 (0.56) L3MBTL1MEN1CYP1A2CYP3A4TSHR
SCHEMBL11879454 0.73 NAAA (0.49) L3MBTL1CNR1CNR2
SCHEMBL14228843 0.73 TSHR (0.44) L3MBTL1MEN1TP53CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365223-B2 Method for selective targeting of apoptotic cells and small molecule ligands used thereof NST NEUROSURVIVAL TECHNOLOGIES LTD (IL) 2008-04-29 US disclosed
US-20060160901-A1 Method for selective targeting of apoptotic cells and small molecule ligands used thereof APOSENSE LTD. (IL) 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160901-A1 Method for selective targeting of apoptotic cells and small molecule ligands used thereof BAD, BAX, CASP3 L3MBTL1 1216/4885MEN1 4258/4885TP53 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.